ARS Pharmaceuticals Inc - fluxo de caixa trimestral (NASDAQ:SPRY)

Financials

Total assets 351.15 M327.32 M313.47 M372.8 M327.65 M Total liabilities 94.36 M98.34 M121.15 M225.15 M213.39 M Total equity 256.8 M228.97 M192.32 M147.66 M114.26 M Total liabilities & shareholders' equities 351.15 M327.32 M313.47 M372.8 M327.65 M Total debt ———97.76 M96.37 M Net debt ———-190.45 M-148.61 M

Notícias

Health Canada aprova spray nasal neffy para alergias graves

Northland inicia cobertura de ações da ARS Pharmaceuticals com classificação de desempenho superior

William Blair reitera classificação Outperform para ARS Pharma após atualização da bula pela FDA

ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)

Leerink eleva preço-alvo da ARS Pharmaceuticals com expansão de vendas

Leerink raises ARS Pharmaceuticals stock price target on sales expansion

ARS Pharmaceuticals supera previsões do 4º trimestre de 2025 e ação sobe

Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises

ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript

Lucro da ARS Pharmaceuticals superou projeções por $0,01; receita supera estimativas

ARS Pharmaceuticals earnings beat by $0.01, revenue topped estimates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates